Literature DB >> 24997136

MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.

Jiali Xu1, Shengwang Tian2, Zhiqiang Yin3, Shuangshuang Wu4, Lingxiang Liu1, Yingying Qian1, Dong Pei1, Wen Gao1, Jing Xu1, Yongmei Yin1, Ping Liu1, Yongqian Shu5.   

Abstract

BACKGROUND: Single-nucleotide polymorphisms (SNPs) in 3'-untranslated regions of cancer-related genes might affect regulation by microRNAs and contribute to cancer patients' outcome.
METHODS: We used public databases to identify SNPs within miRNA-binding sites in deregulated genes in non-small cell lung cancer (NSCLC). A total of 13 SNPs in 10 genes were included and genotyped by SNaPshot assay in 576 NSCLC patients. Associations between SNPs, overall survival (OS) and chemotherapy response were evaluated by Cox regression and logistic regression. We then examined the functionality of the significant polymorphisms.
RESULTS: Two SNPs (TYMS rs2790 and MICA rs9266825) were significantly associated with OS. In the combined analysis, an increasing number of unfavorable loci was associated with a poorer prognosis (P for trend<0.001) and patients having 2-3 unfavorable loci had a 1.61-fold elevated risk of death (95% confidence interval: 1.20-2.15), compared with those carrying 0-1 unfavorable loci. A significant effect of SNPs on platinum-based chemotherapy response was observed among 296 advanced NSCLC patients without surgical operation: rs2790, rs4246215 and rs1882. Further analysis using mRNA expression data from the HapMap suggested that these significant loci (FEN1 rs4246215, HDAC2 rs11391, MICA rs1882 and rs9266825) were closely associated with host genes expression. In vitro functional study for TYMS rs2790 was carried out. Luciferase assay showed a lower expression level for rs2790 G allele as compared with A allele, and the hsa-miR-1248 had an effect on modulation of TYMS gene.
CONCLUSION: Our data indicate that miRNA-binding site SNPs in deregulated genes may serve as candidate prognostic markers of NSCLC clinical outcome.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Chemotherapy; Non-small cell lung cancer; Outcome; Polymorphism; Survival; miRNA

Mesh:

Substances:

Year:  2014        PMID: 24997136     DOI: 10.1016/j.lungcan.2014.06.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.

Authors:  Honglin Dong; Dengke Bao; Xu Guo; Jie Hu; Xiaofei Li; Shaogui Wan; Jinliang Xing
Journal:  Tumour Biol       Date:  2015-04-16

2.  CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells.

Authors:  Ying Yu; Yarong Song; Lulin Cheng; Liang Chen; Bing Liu; Dingheng Lu; Xuexiang Li; Yunxue Li; Fang Lv; Yifei Xing
Journal:  J Exp Clin Cancer Res       Date:  2022-06-02

3.  A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer.

Authors:  Peide Huang; Fengyu Li; Zongchao Mo; Chunyu Geng; Fang Wen; Chunyan Zhang; Jia Guo; Song Wu; Lin Li; Nils Brünner; Jan Stenvang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

4.  Restoration of UPK1A-AS1 Expression Suppresses Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cell Carcinoma Cells Partially by Sponging microRNA-1248.

Authors:  Fang Du; Tao Guo; Chenghua Cao
Journal:  Cancer Manag Res       Date:  2020-04-21       Impact factor: 3.989

5.  Circ-PITX1 Promotes the Progression of Non-Small Cell Lung Cancer Through Regulating the miR-1248/CCND2 Axis.

Authors:  Qianyu Yue; Yanyan Xu; Xiaoli Deng; Shenglan Wang; Jingman Qiu; Baojiang Qian; Yunhui Zhang
Journal:  Onco Targets Ther       Date:  2021-03-09       Impact factor: 4.147

6.  Major Histocompatibility Complex Class I-Related Chain A (MICA) Allelic Variants Associate With Susceptibility and Prognosis of Gastric Cancer.

Authors:  Karen Toledo-Stuardo; Carolina H Ribeiro; Andrea Canals; Marcela Morales; Valentina Gárate; Jose Rodríguez-Siza; Samantha Tello; Marco Bustamante; Ricardo Armisen; Douglas J Matthies; Gerald Zapata-Torres; Patricio González-Hormazabal; María Carmen Molina
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

7.  Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma.

Authors:  Yi He; Yihong Chen; Yuxin Tong; Wenyong Long; Qing Liu
Journal:  PeerJ       Date:  2021-08-06       Impact factor: 2.984

Review 8.  The emerging role of γδ T cells in cancer immunotherapy.

Authors:  Oliver Nussbaumer; Michael Koslowski
Journal:  Immunooncol Technol       Date:  2019-06-26

9.  Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.

Authors:  Dongfang Tang; Yu Chen Zhao; Danwen Qian; Hongliang Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Carolyn Glass; Wen Gao; Qingyi Wei
Journal:  Mol Carcinog       Date:  2019-11-12       Impact factor: 5.139

10.  A Role for Circular Non-Coding RNAs in the Pathogenesis of Sporadic Parathyroid Adenomas and the Impact of Gender-Specific Epigenetic Regulation.

Authors:  Maria P Yavropoulou; Christos Poulios; Nickos Michalopoulos; Ariadni Gatzou; Sofia Chrisafi; Stylianos Mantalovas; Theodosis Papavramidis; Emily Daskalaki; Electra Sofou; Kalliopi Kotsa; Isaak Kesisoglou; Pantelis Zebekakis; John G Yovos
Journal:  Cells       Date:  2018-12-30       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.